Dose-escalation single-center study of RGX-501 for the treatment of homozygous familial hypercholesterolemia

Trial Profile

Dose-escalation single-center study of RGX-501 for the treatment of homozygous familial hypercholesterolemia

Planning
Phase of Trial: Phase I/II

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs RGX 501 (Primary)
  • Indications Hypercholesterolaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jan 2017 According to a REGENXBIO media release, the sponsor has initiated changes to the protocol intended to broaden the eligible and available patient population.
    • 06 Jan 2017 According to a REGENXBIO media release, the company and trial sponsor the University of Pennsylvania had commenced screening for patients with homozygous familial hypercholesterolemia (HoFH) for inclusion in the trial and the patient enrollment anticipated to begin first half 2017.
    • 05 Jul 2016 According to Regenxbio media release, company expects to enroll first patient in the second half of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top